Microneedle-Enabled Exosome Therapy: From Tumor Targeting to Precision Treatment of Complex Diseases Authors: Yuhui Fang, Hao Song, Dongxian Li, Yongyue Jiang, Kehan Zhao, Xinru Qiu, Chongguang Zhao, Xiaoyun Yu, Yumei Li, Xicheng Song Published: 2026 ABSTRACT AbstractExosomes are nanoscale extracellular vesicles (EVs) that mediate intercellular communication by transporting proteins, lipids and nucleic acids. Their biocompatibility, low immunogenicity and intrinsic ability to protect labile cargo make them attractive therapeutic carriers. Yet their clinical translation remains constrained by heterogeneous isolation protocols, variable product purity, inefficient cargo loading, rapid systemic clearance and limited tissue-selective delivery. Engineering strategies, including parental-cell preconditioning, genetic modification, post-isolation cargo loading and surface functionalization, have improved the potency and targeting of exosome-based therapeutics but have not fully solved delivery-related bottlenecks. Microneedle (MN) systems provide a complementary solution by breaching the stratum corneum in a minimally invasive manner and depositing exosomes directly within defined tissue compartments. When integrated with dissolving, hydrogel, cryogenic, core-shell, Janus, threaded or stimulus-responsive MN architectures, exosomes can be retained locally, released in a programmed manner and protected from rapid degradation. This Review first summarizes the biological basis, source-dependent functions and engineering strategies of exosomes, and then outlines the design principles of MN platforms relevant to vesicle delivery. On this basis, we discuss representative studies in which MN systems have been explored to improve the local retention, controlled release and tissue-specific delivery of exosomes in cancer, wound repair, neurological injury, cardiovascular disease, immune-mediated disorders and other regenerative settings. We further summarize the translational barriers that remain for this emerging strategy, including vesicle characterization, potency assays, sterility control, scalable manufacturing, long-term safety, storage stability and batch-to-batch reproducibility.Keywords: microneedles, exosomes, extracellular vesicles, transdermal delivery, cancer immunotherapy, regenerative medicine Biological Properties and Engineering Strategies of Exosomes as Therapeutic Carriers This section outlines the biological rationale for using exosomes as therapeutic carriers and defines the main obstacles that currently limit their translation: inconsistent isolation and characterization, low and variable drug-loading efficiency, insufficient targeting specificity and uncertain potency metrics. We first summarize exosome origin, composition and source-dependent function, and then discuss engineering approaches based on parental-cell modification, physical cargo loading and chemical surface functionalization. The central criterion is not simply whether exosomes can be modified, but whether a given strategy preserves vesicle integrity while improving purity, yield, cargo stability and delivery precision. Discovery and Fundamental Properties of Exosomes In the early 1980s, small membrane-bound vesicles (~50 nm) were first observed in tumor cell culture media, with surfaces exhibiting 5’-nucleotidase activity.1 Subsequent work in reticulocytes suggested that these vesicles originate from late-stage endosomes; intraluminal vesicles accumulate within multivesicular bodies (MVBs), which can fuse with the plasma membrane and are enriched in transferrin receptors and other components.2 Electron microscopy further supported this release mechanism by visualizing extracellular vesicles (EVs) following MVB-plasma membrane fusion. After isolation by ultracentrifugation, these vesicles were termed “exosomes”.3 In current usage, exosomes are commonly discussed as small EVs, usually enriched in particles of ~50-150 nm, although authoritative EV guidelines emphasize that operational definitions should be based on source, separation method and characterization rather than size alone.4–6 Key advantages include nanoscale size, high biocompatibility, the capacity for cargo protection and intercellular communication, immunomodulatory activity, and amenability to engineering. Collectively, these properties underpin the growing interest in exosomes as therapeutic carriers and support their broad potential in disease treatment.7 A schematic overview of exosome biogenesis, engineering strategies, and their diverse functions in intercellular communication is illustrated in Figure 1. Schematic of exosome biogenesis, engineering and function. The diagram illustrates exosome formation from MVBs, bioengineering and cargo-loading strategies, and the diverse roles of exosome uptake in immunity, cancer, neuroprotection and tissue repair. Created by the authors using Adobe Illustrator. Molecular Composition and Information Transfer Function Natural and engineered exosomes can transport proteins, nucleic acids, lipids and small-molecule drugs, thereby enabling therapeutic intervention across multiple disease contexts.8 For example, engineered exosomes have been used to deliver siRNA or shRNA targeting oncogenic KRASG12D in pancreatic cancer models.9 At the molecular level, exosomes contain membrane proteins involved in adhesion and fusion, including integrins and tetraspanins, as well as regulatory molecules that influence metabolism and signal transduction. Their luminal cargo includes microRNAs (miRNAs), messenger RNAs (mRNAs), deoxyribonucleic acid (DNA) fragments and long non-coding RNAs, which can reshape target-cell behavior through transcriptional, post-transcriptional and epigenetic mechanisms.10 However, these biological advantages are meaningful only when vesicles reach the appropriate tissue at sufficient concentrations, which makes efficient and tissue-selective delivery a central translational requirement. Cell-Specific Origin The therapeutic activity and safety profile of exosomes are strongly influenced by their cell of origin.11 B-cell-derived exosomes can carry MHC molecules and support antigen presentation, illustrating how immune-cell origin determines vesicle function.12 Tumor-derived exosomes may contain invasion- and metastasis-related components, indicating that vesicle origin can also introduce disease-promoting risks.13 Tumor-derived vesicles can further reprogram stromal or mesenchymal cells within the tumor microenvironment through transferred proteins and miRNAs.14,15 Therefore, source selection is not a technical detail but a determinant of therapeutic potency, biodistribution, MN compatibility and translational risk.11,13,15 The major exosome sources relevant to MN-assisted delivery are compared in Table 1. Table 1Comparison of Major Exosome Sources Relevant to MN-Assisted DeliveryExosome SourceMain Biological FunctionsRepresentative Cargo/FeaturesAdvantages for MN DeliveryLimitations/RisksBest-Fit ApplicationRepresentative ReferencesMSC-ExoImmune modulation, antioxidant defense, angiogenesis, epithelial repair and scar reductionWnt/beta-catenin-related signals; Nrf2/HO-1-related antioxidant activity; VEGF/Ang-1; miR-126 and Wnt4-associated pathwaysSuitable for local sustained release and phase-specific tissue repairDonor heterogeneity, culture-condition dependence, batch variability and unclear potency metricsWound healing, scarless repair, ischemia-reperfusion injury and spinal cord injury[16–26]ADSC-ExoSkin regeneration, anti-ageing effects, oxidative-stress attenuation and mitochondrial supportAnti-inflammatory and anti-oxidative cargo; mitochondria-enriched vesicles in selected studiesSuitable for dermatological MN delivery and chronic wound repairVariable cargo profiles; donor and culture variability; incomplete mechanism validationSkin ageing, pigmentation disorders and chronic wounds[27–32]BMSC-ExoImmune regulation, mucosal repair and miRNA-mediated tissue repairLPS-preconditioned cargo; miR-378-loaded engineered vesiclesCan be combined with MNs for oral mucosal repair, inflammatory repair and disc repairLoading efficiency and disease-specific potency require validationOral ulcers, intervertebral disc degeneration and inflammation-associated repair[33–40]Macrophage-ExoInflammation regulation, angiogenesis, wound repair or inflammation amplification depending on M1/M2 phenotypeM1-associated miR-155; M2-associated pro-repair signalsUseful for local immune microenvironment remodeling through MN deliveryPhenotype-dependent effects; M1 vesicles may aggravate inflammationDiabetic wound healing, inflammatory disease and tissue repair[41–45]DC-ExoAntigen presentation, T-cell priming and cancer immune activationMHC I/II, CD86 and tumor-antigen-related cargoPotential for local cancer immunotherapy via MN-assisted depositionImmune activation must be controlled; clinical efficacy remains limitedCancer vaccines and tumor immunotherapy[46–48]Treg-ExoImmune suppression and inhibition of pathogenic T-cell responsesImmunosuppressive miRNAs and regulatory signalsMay support local immunomodulation in inflammatory skin or autoimmune diseasesRisk of excessive immune suppression and context-dependent effectsPsoriasis, autoimmune inflammation and transplant-related inflammation[49,50]NK-ExoTumor-cell killing and apoptosis inductionPerforin, granzyme B and FasLPotential for localized antitumor delivery to reduce systemic toxicityManufacturing and potency standardization; possible off-target cytotoxicityCancer immunotherapy[51,52]HUVEC-ExoEndothelial repair, angiogenesis, M2 macrophage polarization and wound healingPro-angiogenic and endothelial-supportive signalsSuitable for MN-assisted delivery in ischemic or diabetic wounds requiring vascular repairSource specificity and safety require further validationDiabetic wound healing and vascular repair[53,54]Tumor-derived ExoTumor antigen presentation or tumor homing; may also promote invasion, metastasis and angiogenesisTumor-associated proteins, miRNAs and matrix-remodeling enzymesPotential diagnostic or immunotherapy relevance if properly engineeredPro-metastatic, pro-angiogenic, immunosuppressive and safety risksCancer diagnosis, tumor antigen delivery and research models[13–15,55]Plant-derived exosome-like nanoparticlesAnti-inflammatory effects, pigmentation-related regulation, hair-growth-associated activity and possible antitumor immune modulationPlant-derived lipids, RNAs and phytochemical-associated componentsScalable source; potential low immunogenicity; suitable for dermatological MN productsNomenclature, purity, mechanism, batch consistency and safety remain unclearSkin pigmentation, inflammation, hair growth and topical/MN-assisted dermatology[29,56–58] Comparison of Major Exosome Sources Relevant to MN-Assisted Delivery Stem Cell-Derived Exosomes Stem cell-derived exosomes are widely investigated as cell-free therapeutic candidates because they may retain part of the regenerative potential of their parent cells while reducing risks associated with live-cell transplantation.16,59 MSC-Exo are particularly relevant to regenerative medicine because mesenchymal stem cells possess immunomodulatory properties and broad translational potential.16,60 Neural stem cell-related evidence also supports the broader concept that stem-cell-derived products may be useful in neural regeneration.61 In hair-regeneration models, MSC-derived vesicles have been associated with Wnt/beta-catenin-related signaling and hair-follicle stem-cell activity.62–64 MSC-Exo can activate antioxidant defense pathways such as the Nrf2/HO-1 axis, which is relevant to oxidative-stress-associated tissue injury.17,25,26 MSC-Exo and preconditioned MSC-derived vesicles can modulate macrophage polarization and inflammatory signaling, supporting their use in inflammation-associated repair.18,33–36 MSC-Exo may also promote angiogenesis and epithelial repair through pro-regenerative signals such as VEGF-related, miR-126-related and Wnt4-associated pathways.20–23 At the same time, MSC-Exo can limit excessive fibrosis by regulating fibroblast activation and extracellular-matrix deposition.18,22,24 In addition to MSC-Exo, adipose-derived stem cell exosomes (ADSC-Exo) can recapitulate several reparative properties of their parent cells. ADSC-Exo have been explored for skin ageing and pigmentation-related indications through anti-inflammatory, antioxidant and anti-melanogenic effects.27–31,65 Mitochondria-enriched extracellular vesicles from ADSC may support chronic wound repair by improving mitochondrial function in damaged tissues.32 Immune Cell-Derived Exosomes Immune cell-derived exosomes are important mediators of immune-cell communication because they can transfer proteins, lipids, mRNAs and miRNAs between immune and target cells.66,67 Macrophage-derived exosomes display functional plasticity that reflects the phenotype of their parent macrophages.41,42 M1 macrophage-derived exosomes can contain pro-inflammatory mediators such as miR-155 and may sustain inflammatory signaling.41 By contrast, M2 macrophage-derived exosomes have been linked to angiogenesis, macrophage phenotype switching and cutaneous wound repair.42,43,45 M2 macrophage-derived exosome-loaded MN systems have further been used to enhance diabetic wound healing, supporting their relevance to local immune microenvironment remodeling.44 DC-derived exosomes carry antigen-presentation and co-stimulatory molecules, including MHC I/II and CD86, making them relevant to cancer immunotherapy.46 Clinical studies of dendritic-cell-derived exosomes in melanoma and non-small-cell lung cancer suggest acceptable safety and immune activation potential in selected settings.47,48 Treg-derived exosomes can transfer immunosuppressive miRNAs and suppress pathogenic T helper responses.49 Treg-derived exosome-based MN systems have been explored for psoriasis, indicating their potential in local immune regulation.50 NK-cell-derived exosomes contain cytotoxic proteins such as perforin, granzyme B and FasL and can induce tumor-cell apoptosis in preclinical models.51 Recent studies further support NK-cell-derived exosomes as a potential cell-free platform for cancer therapy, although translational standardization remains challenging.52 For MN-assisted delivery, immune cell-derived exosomes are most relevant to local immunotherapy, inflammatory skin disease, wound repair and tumor immune modulation, but their immune potency requires careful control to avoid context-dependent inflammation, excessive immune suppression or off-target immune effects.41,49,51,52,66,67 Plant-Derived Exosome-Like Nanoparticles Plant-derived exosome-like nanoparticles have attracted interest as potentially scalable and low-immunogenic vesicle sources.56 Extracellular vesicles derived from plant leaves and stems have been reported to exert anti-melanogenic effects in melanoma cells and human skin models.29 Plant-derived vesicles from Polygoni Multiflori Radix have been linked to hair-growth-associated pathways through putative miRNA cargo.57 Ginseng-derived exosome-like nanoparticles have been reported to modulate the tumor microenvironment and exert anti-glioma activity.58 Therefore, plant-derived vesicle-like nanoparticles may be relevant to dermatological, inflammatory and topical or MN-assisted applications.29,56–58 However, their nomenclature, purity standards, batch consistency, cross-kingdom mechanisms and long-term safety remain less clearly defined than those of mammalian-cell-derived exosomes.56–58 Exosomes from Other Sources HUVEC-derived exosomes have been implicated in vascular homeostasis and diabetic wound repair by improving endothelial function and promoting M2 macrophage polarization.53 GelMA/PEGDA MN patches loaded with HUVEC-derived exosomes have also been reported to promote diabetic wound healing, supporting their compatibility with MN-assisted vascular repair strategies.54 Tumor-derived exosomes can carry matrix-remodeling enzymes and other tumor-associated signals that promote invasion, metastasis and angiogenesis.13,55 Ovarian cancer cell-derived exosomes and chronic lymphocytic leukemia cell-derived exosomes can induce stromal or mesenchymal cells to acquire tumor-supporting phenotypes.14,15 Although tumor-derived vesicles may have diagnostic, antigen-delivery or tumor-homing relevance, their pro-metastatic and immunosuppressive risks require careful safety assessment before therapeutic use.13–15,55 Exosome Engineering, Cargo Loading and Isolation Strategies As source- and context-dependent functions of exosomes become clearer, engineering strategies have been developed to enhance therapeutic performance.68 These strategies can be broadly divided into parental-cell engineering before vesicle release and post-isolation modification after vesicle purification.69 Parental-cell engineering often preserves membrane integrity and supports stable production of functional vesicles, whereas post-isolation loading allows direct incorporation of therapeutic cargo but may compromise vesicle integrity, reproducibility or purity depending on the method.69,70 The major engineering and loading strategies are compared in Table 2. Table 2Comparison of Exosome Engineering and Cargo-Loading StrategiesStrategyTypical Cargo/UseMechanismAdvantagesLimitations/RisksRepresentative ReferencesParental-cell pretreatmentFunctional proteins/RNAs enriched through culture stimuliStimulates parent cells before vesicle releasePreserves vesicle membrane and can improve biological potencyCulture-condition dependence and variable potency[69,71–74]Genetic engineering of parental cellssiRNA, shRNA, miRNA, targeting ligandsTransgene expression in parental cells and incorporation into vesiclesStable cargo or ligand production; supports targetingTransgene stability, off-target effects and manufacturing control[9,70,75–79]Surface ligand displayPeptides, antibodies, targeting motifsFusion to CD9/CD63/CD81/LAMP-2b/PDGFR or related scaffoldsImproves tissue or cell targetingMay alter vesicle tropism or immunogenicity[76–81]ElectroporationmiRNA, siRNA, nucleic-acid cargoElectric-field-mediated membrane permeabilizationWidely used for nucleic-acid loadingAggregation and variable loading efficiency may occur[82]SonicationmiRNA or small moleculesTransient lipid-bilayer disruptionHigher cargo access to vesicle lumenPotential membrane damage; optimization required[37,38]Cellular nanoporationmRNA, nucleic acids, targeting peptidesLarge-scale cellular nanoporation before exosome harvestHigh production and exogenous nucleic-acid enrichmentRequires specialized platform and validation[83]Liposome-exosome fusionLarge cargo, peptides, nucleic acids, drugsMembrane fusion of liposomes and exosomesCombines loading capacity with biological compatibilityHybrid identity and regulatory classification are complex[84,85]Chemical surface modificationAntibodies, peptides, aptamersAmine coupling, click chemistry or related conjugationEnables post-isolation targeting modificationResidual reagent toxicity and reproducibility concerns[81,86] Comparison of Exosome Engineering and Cargo-Loading Strategies Parental-Cell Engineering and in situ Modification Pretreatment of parental cells with defined stimuli can alter exosomal protein and RNA cargo without directly disrupting the vesicle membrane.69,71 Circadian cues, inflammatory stimulation and three-dimensional culture conditions may reshape vesicle cargo and thereby tune regenerative or immunomodulatory functions.72–74 Genetic engineering enables parental cells to generate vesicles that carry therapeutic nucleic acids or display targeting ligands, including peptides and antibodies.9,75 Surface-display scaffolds such as CD9, CD63, CD81, LAMP-2b and PDGFR transmembrane domains have been used to improve vesicle targeting.76,77 For neurological delivery, LAMP-2b fused to rabies virus glycoprotein peptide has been used to enhance neuronal targeting and blood-brain-barrier penetration.75,78,79 In cancer models, ligand-displaying exosomes can improve tumor accumulation through mechanisms such as EGFR or RGD-associated targeting.76,80 These strategies increase the design space of exosome therapeutics, but genetic modification also introduces concerns regarding off-target effects, transgene stability, potency drift and manufacturing control.5,6,70 Physical and Chemical Cargo-Loading Approaches Electroporation, sonication, extrusion, incubation, freeze-thaw cycles, saponin-assisted permeabilization, click chemistry and liposome-exosome fusion have all been used to load or modify exosomes.69,81,84 Ultrasonication transiently disrupts the lipid bilayer to facilitate cargo entry and has been used to load miRNA cargo into BMSC-derived exosomes in disc-degeneration-related models.40 Cellular nanoporation can generate large quantities of exosomes enriched with exogenous nucleic acids and targeting peptides, making it attractive for scalable nucleic-acid delivery.83 Liposome-exosome fusion combines the loading capacity of liposomes with selected biological properties of exosomes and has been used to generate hybrid carriers, including ziconotide-loaded liposome-exosome systems integrated with MN arrays.84,85 Chemical modification can attach antibodies, peptides or aptamers to exosome surfaces, including through click chemistry; however, residual reagents such as copper must be controlled to reduce cytotoxicity.81 Antibody-modified exosomes targeting the CD47-SIRPalpha axis illustrate how surface functionalization can be used to alter tumor immune interactions.86 Isolation, Characterization and MISEV-Related Considerations Post-isolation modification requires reliable exosome purification before cargo loading or surface functionalization.69 Differential ultracentrifugation remains widely used, but it is time-consuming and can co-isolate protein aggregates or other EV subpopulations.87,88 Density-gradient separation can improve purity but increases processing time and may reduce throughput.87 Ultrafiltration and polymer precipitation are operationally simple but often require additional clean-up to improve purity.87,88 Immunocapture can enrich defined marker-positive vesicles but may not represent heterogeneous EV populations and is difficult to scale.87 Emerging acoustic, microfluidic and electromagnetic approaches provide rapid processing for small volumes but require validation for standardized production.87,88 In accordance with MISEV guidance, isolation methods should be reported together with particle characterization, protein markers, purity indicators and operational definitions rather than relying on size alone.4–6 A comparison of exosome isolation methods is provided in Table 3. Table 3Comparison of Exosome Isolation Methods and MISEV-Related ConsiderationsIsolation MethodPurityYieldReproducibility/ScalabilityAdvantagesLimitationsMISEV-Related ConsiderationsRepresentative ReferencesDifferential ultracentrifugationModerateModerateOperator- and protocol-dependent; limited scalabilityWidely used and accessibleTime-consuming; co-isolates protein aggregates and EV subtypesReport rotor, g force, time and characterization markers[6,87,88]Density-gradient separationHighLow to moderateLess scalableImproves purity by density separationLong processing time and lower throughputUseful for high-purity analytical preparations[87,88]Size-exclusion chromatographyModerate to highModerateRelatively reproducible and scalable with columnsGood preservation of vesicle integrityDilution and limited sample capacityCombine with protein/particle purity assessment[87,88]UltrafiltrationModerateModerate to highScalable but membrane-dependentFast and operationally simpleMembrane clogging and shear-related lossReport membrane cut-off and recovery[87,88]Polymer precipitationLow to moderateHighEasy to scaleSimple and high recoveryPolymer/protein contamination; often requires clean-upNot sufficient alone for functional therapeutic preparations[87,88]ImmunocaptureHigh for marker-positive EVsLow to moderateMarker-dependent and less scalableSpecific enrichment of target populationsMay miss heterogeneous vesicle populationsReport antibody markers and captured population[87,88]Microfluidic/acoustic/electromagnetic methodsVariableVariablePromising but requires validationRapid processing and low sample volumeLimited standardization and scale-up dataNeeds orthogonal characterization and benchmarking[87,88] Comparison of Exosome Isolation Methods and MISEV-Related Considerations Artificial Exosomes, Biomimetic Vesicles and Hybrid Nanocarriers Artificial exosomes, exosome mimetics, biomimetic vesicles and exosome-nanoparticle hybrids broaden the design space beyond naturally secreted vesicles.68,69 Exosome-mimetic hybrid vesicles can combine membrane-derived biological cues with engineered nanocarrier properties, potentially improving drug loading, tumor targeting or manufacturability.68,69 Liposome-exosome hybrids can increase cargo capacity while retaining selected vesicle-associated compatibility, as illustrated by liposome-exosome fusion strategies for peptide or nucleic-acid delivery.84,85 These systems may be useful when native exosomes have insufficient cargo loading, limited scalability or heterogeneous potency, but their biological identity, safety profile and regulatory classification may be more complex than those of native EVs.5,6,69,70 For MN-assisted delivery, hybrid carriers are especially relevant when local retention, vesicle protection and controlled release must be balanced with higher drug-loading capacity. Synergistic Effects of Exosomes and Microneedle Delivery Systems This section explains why MNs are particularly well suited to exosome delivery. Conventional administration routes are limited by rapid systemic clearance, poor penetration across biological barriers, low local retention and, in the case of repeated injections, tissue trauma and infection risk.89–93 MN-based transdermal or local delivery addresses these limitations by creating controlled microchannels and depositing exosomes within defined tissue layers.90,93 A representative approach is the incorporation of exosomes into hyaluronic-acid-based MN patches, which combine minimally invasive delivery with local retention and sustained release. The fabrication process of exosome-loaded hyaluronic acid MN patches is illustrated in Figure 2. Schematic of the fabrication process for exosome-loaded hyaluronic acid (HA) MN patches. Created by the authors with BioRender.com. Intravenous administration can distribute vesicles systemically but is constrained by rapid clearance and poor biodistribution.89 Local injection can increase regional exposure but may cause tissue trauma, leakage and inconsistent retention.91 Passive topical or transdermal delivery is limited by the stratum corneum, which permits passive diffusion mainly of small and sufficiently lipophilic molecules; the 500-Da rule illustrates this barrier for passive skin absorption.92 Hydrogel-based local delivery can improve retention but may still be limited by tissue penetration and dose precision.94,95 By contrast, MNs can bypass the stratum corneum, reduce injection-associated pain and create localized depots for sustained release.90,93 Compared with conventional hypodermic needles, MNs enable minimally invasive access across the epidermal barrier while limiting penetration into deeper tissues (Figure 3). For exosome therapy, the key advantage of MNs is not merely tissue penetration but the ability to preserve vesicle bioactivity while reshaping local concentration, residence time and release kinetics. Conventional routes and MN-mediated delivery are compared in Table 4. Visual representation of skin layers and three methods of antigen delivery: (a) hypodermic needle injection to the subcutaneous space, (b) perpendicular (ie, 90 degrees) MN insertion crossing the epidermis and entering the dermis, and (c) angled MN insertion targeting the epidermis. Created by the authors with BioRender.com. Table 4Comparison of Conventional Administration Routes and MN-Mediated Exosome DeliveryRouteMain AdvantagesMain LimitationsRelevance to Exosome DeliveryRepresentative ReferencesIntravenous injectionSystemic access and simple administrationRapid clearance, nonspecific biodistribution and systemic exposureUseful for systemic disease but inefficient for localized tissue retention[89]Local injectionHigh local dose near target sitePain, leakage, tissue trauma, infection risk and inconsistent retentionUseful for accessible sites but repeated injection is problematic[91]Topical/passive transdermal deliveryNon-invasive and patient-friendlyStratum-corneum barrier and poor vesicle penetrationPoor suitability for intact vesicles without enhancement[90,92]Hydrogel-based local deliveryImproves retention and sustained releaseLimited penetration and variable dose distributionUseful when local depot formation is sufficient[94–96]MN-mediated deliveryMinimally invasive tissue access, local deposition and controlled releaseLimited payload, manufacturing consistency and depth constraintsBest suited for skin, mucosa, wounds, superficial lesions and accessible organs[90,93,97–119] Comparison of Conventional Administration Routes and MN-Mediated Exosome Delivery Accordingly, the value of MNs in exosome therapy should be evaluated by how needle architecture, matrix composition, loading mode, dissolution kinetics and stimulus responsiveness influence exosome loading, protection, release behavior, local biodistribution, cellular uptake and therapeutic performance. This delivery-performance relationship provides the rationale for linking MN design parameters directly to exosome potency and disease-specific outcomes. Optimized Design of Microneedle Technology for Exosome Delivery Effective MN-exosome systems must match needle geometry, material chemistry and release kinetics to the target tissue and pathological context. Important design criteria include penetration depth, mechanical strength, temperature compatibility, exosome stability, loading efficiency, release duration, clinical usability and long-term safety. The principal MN platforms relevant to exosome delivery are compared in Table 5. Table 5Comparison of MN Platforms for Exosome DeliveryMN PlatformTypical Materials/DesignLoading ModeRelease BehaviorAdvantages For ExosomesLimitationsRepresentative ReferencesDissolving MNsHA, polymers, soluble matricesExosomes embedded in dissolvable matrix or tipsRapid to sustained release depending on matrixSimple, minimally invasive and residue-freePayload and stability can be limited[90,93,102,120]Hydrogel-forming MNsGelMA, PEGDA or swelling hydrogelsExosomes retained in hydrogel networkSustained release after swellingGood local retention and protectionMechanical strength and sterilization must be controlled[17,19,54]Cryogenic MNsFrozen or low-temperature molded matricesThermosensitive cargo loaded at low temperatureRapid melting/release after insertionProtects labile biologicsCold-chain requirement[100,102]Coated MNsCargo coated on solid MN surfaceSurface coatingFast release after insertionSimple delivery of small dosesLimited loading and coating uniformity[99]Hollow MNsHollow channels or capillary-like structuresInfusion or sampling through lumenControllable injection or ISF samplingCan deliver or collect fluidsClogging and device complexity[18,121]Core-shell MNsHydrophilic shell plus hydrophobic coreDifferent cargos in shell/corePhase-specific or sequential releaseMatches inflammation and repair phasesComplex fabrication and QC[18,102]Janus MNsAdhesive inner layer and anti-adhesion outer layerExosomes in tissue-facing layerRetained local release with barrier functionUseful for moist or adhesion-prone tissuesComplex design and site-specific validation[101]Threaded/anchoring MNsThreaded or hook-like architectureExosomes in porous or degradable matrixSustained release with anchorageImproves retention in soft tissuesRequires specialized fabrication[40,103]Stimulus-responsive MNspH, redox, glucose, light, heat, electricity or magnetic responsivenessExosomes or co-cargo in responsive matrixOn-demand or disease-triggered releasePotentially precise spatiotemporal controlStimulus reproducibility and biosafety concerns[104–119] Comparison of MN Platforms for Exosome Delivery Specific Microneedle Design Region-specific therapy addresses the spatial heterogeneity of human tissues by designing hierarchical distributions of physical structures or functional components, thereby achieving anatomical adaptability and localized treatment. Depth-specific designs are relevant because epidermal and mucosal thickness varies substantially across anatomical regions; adjustable MN systems have therefore been developed to accommodate different penetration-depth requirements.90,93,99 Temperature-specific designs are important because many exosome formulations are thermosensitive, and fabrication at room temperature or above 30 ℃ may compromise vesicle activity. Cryogenic MNs protect labile biologics by low-temperature molding and cold storage, although cold-chain logistics remain a major translational barrier.100 Functional specificity can be achieved through Janus, core-shell, hollow or retention designs that regulate tissue adhesion, phase-specific release, sampling or sustained implantation.18,20,101,102 Structure-specific MNs, including threaded or hook-shaped arrays, can improve anchorage and local retention in soft tissues or anatomically specialized sites such as the annulus fibrosus or tendon.40 Stimulus-Responsive Microneedles Stimulus-responsive MNs integrate bioresponsive materials with micro- and nanofabrication to enable spatiotemporal control over drug release.104–106 Exogenous stimuli such as light, ultrasound, electricity, magnetic fields or heat can provide temporal control, although clinical practicality depends on stimulus penetration depth, device availability and safety.104–106,122 Photo-, ultrasound- or NIR-responsive MNs can trigger drug release, local heat or ROS generation and are most suitable for superficial lesions when penetration depth is limited.107–110 Electro-, mechanical-, magnetic- and heat-responsive MNs can modulate cargo release by external fields, strain or temperature-responsive materials.111–114 Endogenous stimulus-responsive MNs use disease-associated cues such as acidic pH, enzyme activity, glucose or redox gradients to provide closed-loop release without external devices.115–118 For exosome delivery, these systems are valuable only if responsiveness is reproducible and compatible with vesicle integrity, which makes scalable quality control, stimulus sensitivity and long-term biosafety essential translational requirements. Design Parameters Governing Exosome Loading, Release and Delivery Performance Needle length and tip geometry determine whether exosomes are deposited in the epidermis, dermis, mucosa, wound bed or deeper tissue compartments.90,93,97 Matrix composition influences both mechanical strength and vesicle stability during fabrication, storage and insertion.98–100 Dissolution or degradation kinetics control early burst release, sustained release or phase-specific release, as seen in core-shell and hydrogel-based MN systems.18,19,102 Loading mode is equally important: exosomes may be embedded within the matrix, concentrated in the tip, adsorbed onto porous materials or retained within hybrid hydrogel networks.18,19,123 Tissue adhesion and retention structures can reduce leakage and increase local residence time, which is relevant for uterine, tendon, wound and intervertebral-disc applications.20,40,98,101 Therefore, MN-mediated exosome therapy should be analyzed as a combined design problem that integrates vesicle source, engineering method, MN platform, loading strategy, release profile and disease microenvironment. The main structural components, materials, fabrication strategies and therapeutic applications of MN systems are summarized in Figure 4. Schematic illustration of MN systems, including structural components, materials, fabrication methods and therapeutic applications. Created by the authors with BioRender.com. Precision Applications of Microneedle-Delivered Exosome Systems in Tumor and Disease Treatment This section evaluates how MN-exosome systems can be adapted to disease-specific barriers, including tumor heterogeneity, chronic inflammation, impaired angiogenesis, fibrosis, ischemia, immune dysregulation and tissue-specific anatomical constraints. The relevant benchmarks are targeted accumulation, local retention, programmed release, therapeutic mechanism, comparative advantage over standard delivery and feasibility for translation. Therapeutic studies are distinguished as proof-of-concept, preclinical or clinical where possible, because most current evidence remains at the proof-of-concept or small-animal preclinical stage. Cancer Treatment Exosomes are attractive carriers for tumor therapy because they can promote intracellular delivery and can be engineered to modulate immune responses in the tumor microenvironment.124 MN-based delivery adds local deposition and controlled release, potentially increasing tumor-site exposure while reducing systemic toxicity.119,125–127 However, the current evidence base remains largely preclinical. Tumor heterogeneity, dense extracellular matrix, abnormal vasculature and limited deep-tumor penetration remain major barriers to effective MN-exosome therapy for cancer. Drug Delivery Immune checkpoint blockade (ICB) therapy enhances antitumor responses by inhibiting immunosuppressive pathways such as PD-1/PD-L1 and CTLA-4, but response rates remain suboptimal and immune-related adverse events remain clinically important.128–131 Localized delivery of ICB agents has been proposed to maximize tumor-local immune activation while reducing systemic adverse effects.125,126 Han et al summarized local and targeted strategies that combine vesicle engineering and MN platforms for immune-checkpoint modulation (Figure 5).127 In representative systems, engineered vesicles can provide immune-modulatory signals, whereas MNs support transdermal deposition, controlled release and prolonged local retention.119,127 The pancreatic cancer microenvironment, which is characterized by fibrosis and immune suppression, illustrates why additional matrix-penetrating and immunomodulatory strategies may be required beyond conventional nanodelivery.132 Representative MN systems for cancer immunotherapy and tumor diagnosis. (a) MN patch-based anti-PD-1 delivery platform; m-HA, matrix hyaluronic acid; CAT, catalase. (b) Interstitial fluid extraction using hydrogel MNs for exosome capture. Adapted with permission from References.121,127. A critical limitation is that patch-like MN systems are best suited for skin, mucosa, superficial tumors, accessible lesions or postsurgical tumor beds. For deep-seated tumors such as pancreatic cancer, conventional transdermal MNs cannot directly reach the tumor mass, and delivery may require intraoperative placement, endoscopic assistance, implantable MN-like systems, or combination with systemic nanocarriers.125,132 Therefore, cancer applications should be interpreted according to anatomical accessibility rather than assuming that MN-based exosome delivery is broadly applicable to all solid tumors. Tumor Detection Tumor detection increasingly uses molecular biomarkers in biofluids, including circulating tumor DNA, miRNAs, circulating tumor cells and exosomes.133,134 Interstitial fluid has attracted attention as a diagnostic matrix because it contains tissue-proximal proteins and vesicles that may reflect local disease states.135 Park et al developed hydrogel MNs for extracting exosomes from interstitial fluid in colorectal cancer model mice.121 Exosomes captured by glypican-1 antibodies were recovered and used for cancer diagnosis, supporting the proof-of-concept value of MN-assisted exosome sampling.121 A schematic summary of MN-based immune-checkpoint delivery and MN-assisted ISF exosome extraction is shown in Figure 5. Skin and Wound Repair Skin Scar, Oral Ulcers and Diabetic Wound Healing MN-exosome systems can promote skin repair by coordinating inflammation resolution, angiogenesis, fibroblast activity, matrix remodeling and re-epithelialization.136 In scar repair, core-shell MNs can coordinate early release of mangiferin with prolonged release of MSC-Exo, supporting phase-specific inflammation control and tissue regeneration.18 In oral ulcers, silk fibroin MNs loaded with LPS-preconditioned BMSC-Exo achieved deep mucosal penetration and promoted wound healing, illustrating the relevance of MNs for mucosal vesicle delivery.39 In diabetic wounds, adaptable indwelling MNs containing MSC-Exo improved local delivery and wound repair20, whereas MOF-based MNs loaded with exosomes combined electrostatic loading, acidic microenvironment-responsive release, Zn2+-associated antibacterial effects and pro-angiogenic signaling.123 Exosome- and antibiotic-loaded MN systems have also been used to remodel high-glucose-associated macrophage dysfunction and clear biofilms in diabetic MRSA infection models.137 These examples remain primarily preclinical but show how MN architecture can link release kinetics, immune remodeling and tissue regeneration. Figure 6 summarizes representative diabetic-wound MN-exosome systems. Representative MN-exosome systems for diabetic wound healing. (a) Retained/adaptable indwelling MNs continuously releasing exosomes at the implant site to promote healing. (b) Illustration of MOF and exosome loaded MN patch for promoting wound healing. Exosomes autonomously assemble on the surface of MOF loaded microneedles through electrostatic attraction. After insertion, the microneedles deliver MOF and exosomes to the subcutaneous layer through a minimally invasive drug delivery approach, allowing for their sustained release. The healing mechanisms of the MN system were composed of three steps: sterilization, angiogenesis and antiinflammation. i) MOF incorporated into MN patches were capable of inhibiting microbial pathogen growth at the wound surface ii) MOF and exosomes were transported into the subcutaneous layer through the needle tips, where their synergistic effect can induce blood vessel growth. iii) inhibit chronic wound-associated inflammation by macrophages polarization. Adapted with permission from References.20,123 Tendon-Bone Interface Healing Tendon-bone interface healing is limited by insufficient mechanical integration and inflammatory microenvironmental dysregulation. A triphasic MN delivery system combined optimized exosomes with layered MN architecture to enhance tendon-to-bone healing.98 Grapefruit-derived exosome-loaded MN systems have also been reported to reduce oxidative stress, promote collagen synthesis and induce M2 macrophage polarization in tendinopathy models.138 These studies highlight the need to integrate tissue anchorage, sustained release and microenvironmental modulation in musculoskeletal applications. Alkaline Corneal Burns Alkaline corneal burns involve epithelial injury, sustained inflammation, apoptosis, necrosis and fibrosis.139–141 ADSC-derived exosomes provide immunomodulatory and regenerative signals, but eye drops and subconjunctival injection often show poor retention and limited ocular bioavailability.142,143 Dissolvable MNs can improve engineered exosome penetration and retention in the corneal stroma.120 Anti-TNF-alpha-antibody-conjugated ADSC-Exo-loaded MNs illustrate how exosome engineering and MN delivery can be integrated for local, multi-targeted ocular therapy.120 Neurological Disorders Spinal Cord Injury After spinal cord injury, oxidative stress, neuroinflammation and glial scar formation create an inhibitory microenvironment that limits neural regeneration.144,145 MSC-Exo can modulate this microenvironment, and 3D-culture-derived exosomes may better preserve donor-cell phenotypes than conventional 2D-culture-derived vesicles.94,146,147 Han et al developed a GelMA MN hydrogel platform loaded with 3D-MSC-Exos for in situ sustained release.19 Compared with injection, this system increased exosome retention and maintained release for up to 72 h in rat SCI models, improving functional recovery and reducing neuroinflammation.19 The overall design of the GelMA-MN@3D-Exo system is shown in Figure 7. Representative MN-exosome systems for spinal cord injury, myocardial infarction-related fibrosis and psoriasis. (a) Overall design of GelMA-MN@3D-Exo for treatment of SCI in rats. (b) MN patch loaded with exosomes containing miR-29b mimics for myocardial infarction-related cardiac fibrosis. (c) Comprehensive psoriasis therapy by rExo@DMF MNs. Adapted with permission from References.19,50,82 Abbreviations: rExo, regulatory T cell-derived exosomes; DMF, dimethyl fumarate; MNs, microneedles; tDCs, tolerogenic dendritic cells; Tregs, regulatory T cells. Cardiovascular Disease Cardiac Fibrosis Following Myocardial Infarction Cardiac fibrosis following myocardial infarction is mediated in part by myofibroblast differentiation and abnormal extracellular-matrix deposition.148–150 Current biomaterial and drug-delivery approaches remain limited by insufficient targeting and stability.96 Yuan et al developed an exosome-based MN patch for localized myocardial delivery of miR-29b.82 HUCMSC-derived exosomes were loaded with miR-29b mimics by electroporation and integrated into a biodegradable MN array, improving local retention and controlled release in a myocardial infarction mouse model.82 This approach demonstrates how exosome cargo engineering and MN-mediated local delivery can be combined to address fibrotic remodeling. A schematic representation of the miR-29b-loaded exosome MN patch is shown in Figure 7. Myocardial Infarction An MN-microbot hybrid system using asymmetric CaCO3 particles has also been developed for exosome delivery after myocardial infarction.151 The platform moves within the acidic infarct microenvironment, supports deeper tissue delivery, enables rapid VEGF release and improves cardiac function in animal models.151 Although promising, this strategy remains preclinical and requires further validation of biodistribution, repeat-dose safety and manufacturability. Immune-Mediated Diseases Rheumatoid Arthritis Rheumatoid arthritis is characterized by chronic inflammation mediated in part by TNF-alpha.102 Wen et al developed cryomicroneedles loaded with milk-derived exosomes encapsulating TNF-alpha siRNA for percutaneous acupoint administration. In this system, exosomes serve as siRNA carriers, whereas cryogenic MNs enable transdermal delivery and reduce the drawbacks of injection-based administration.102 This example demonstrates how MNs can combine local tissue access with nucleic-acid-loaded vesicles for inflammatory disease, although clinical translation will require potency, safety and dosing validation. Psoriasis Local immune dysregulation in psoriasis creates a need for lesion-directed therapies that avoid systemic immune suppression. rExo@DMF MNs integrate regulatory T-cell-derived exosomes with dimethyl fumarate and suppress keratinocyte hyperproliferation and local inflammation while promoting Treg differentiation.50 A dual-segment light-guiding MN system containing MXene photothermal materials and M2 exosomes has also been developed for localized photothermal and immunomodulatory treatment of psoriasis.152 These examples illustrate how MN structure can be adapted to skin-specific optical and immune constraints. The therapeutic design of rExo@DMF MNs for psoriasis is shown in Figure 7. Treatment for Other Diseases Ischemia-Reperfusion Injury Ischemia-reperfusion injury involves oxidative stress, inflammation and cell death. GelMA MNs loaded with 3D-culture-derived exosomes improved local retention and supported sustained release for up to 72 h in ischemia-reperfusion models.17 A related exosome-loaded MN patch has been reported to ameliorate renal ischemia-reperfusion injury after transplantation.153 These studies support a general design principle: exosome potency and local delivery must be optimized together. Intrauterine Adhesions Intrauterine adhesions can cause infertility and menstrual dysfunction, and conventional local delivery systems may show weak tissue adhesion and rapid degradation.95,154–156 A Janus MN patch combining an inner adhesive, exosome-loaded layer with an outer anti-adhesion barrier improved MSC-Exo retention in the uterine environment and supported epithelial proliferation and angiogenesis.101 This dual-function design addresses both tissue regeneration and recurrence prevention. Chronic Pain Chronic pain management is limited by opioid tolerance, dependence and adverse effects.157 A GelMA MN array delivering ziconotide-loaded liposome-exosome hybrid carriers improved delivery efficiency and sustained analgesic activity in preclinical pain models.85 This example illustrates how exosome-hybrid carriers and MNs can be integrated to improve local peptide delivery. Intervertebral Disc Degeneration Intervertebral disc degeneration is characterized by extracellular-matrix degradation, annulus fibrosus injury and impaired mitochondrial quality control.158 BMSC-derived exosomes have been explored for IVDD therapy but are limited by low delivery efficiency and rapid clearance.37 miR-378 can regulate mitochondrial homeostasis by modulating the PDK-Akt pathway and mitophagy.38 Hu et al loaded miR-378 into BMSC-derived exosomes and incorporated the engineered vesicles into threaded MNs designed for annulus fibrosus repair.40 The threaded architecture improved anchorage and local retention, whereas the biodegradable porous matrix supported sustained release.40 Disease-specific applications, therapeutic payloads, MN designs and evidence stages are summarized in Table 6. Table 6Disease Applications, MN-Exosome Design Features and Evidence LevelsDisease/ApplicationExosome Source or CarrierMN Design/TypeCargo/Loading/Release FeatureEvidence StageMajor OutcomeLimitationsReferencesCancer immunotherapyEngineered vesicles/PD-1-related systemsDissolving or local MN conceptsLocal immune-checkpoint modulationProof-of-concept/preclinicalEnhanced local immune activation with reduced systemic exposure proposedMainly superficial or accessible lesions; deep tumors remain difficult[119,125–127]Pancreatic cancer contextMultifunctional nanodelivery systemsN/A or potential local-assisted deliverySTING agonist, cytotoxic drug and matrix-penetrating componentsPreclinical/conceptualTumor microenvironment remodelingDeep-seated tumor access remains a major limitation[132]Cancer diagnosisExosomes captured from ISFHydrogel MNsGPC-1 antibody-mediated exosome capturePreclinical proof-of-conceptExosome extraction from ISF for colorectal cancer detectionNeeds clinical biomarker validation[121,133–135]Scarless skin repairMSC-ExoCore-shell MNsMangiferin burst release plus sustained MSC-Exo releasePreclinicalCoordinated anti-inflammatory and regenerative repairTranslation requires manufacturing and safety validation[18],[159]Oral ulcerLPS-preconditioned BMSC-ExoSilk fibroin MNsDeep mucosal penetration (~480 μm)PreclinicalEnhanced mucosal healing and microbial balanceHuman mucosal safety not established[39,160]Diabetic woundMSC-ExoAdaptable/indwelling MNsSustained exosome releasePreclinicalImproved tissue permeability and wound repairBatch consistency and long-term safety unclear[20]Diabetic woundExosomes with MOF/Zn2+ systemMOF MNsElectrostatic loading and acidic wound-responsive releasePreclinicalAntibacterial, anti-inflammatory and pro-angiogenic effectsMOF degradation and safety require validation[123]Infected diabetic woundUmbilical-cord MSC-derived H-Exos and antibioticsExoV-ExoL@MNsImmune rejuvenation plus bacterial-responsive antibiotic releasePreclinicalMacrophage rejuvenation and biofilm clearanceComplex formulation and regulatory pathway[137]Tendon-bone healingOptimized/circadian-regulated exosomesTriphasic MNsSpatially organized exosome deliveryPreclinicalImproved tendon-to-bone repairMechanical durability and scale-up uncertain[98]Corneal alkali burnEngineered ADSC-ExoDissolvable MNsAnti-TNF-alpha antibody-conjugated exosomesPreclinicalImproved corneal stromal retention and healingOcular safety and dosing require validation[120,139–143]Spinal cord injury3D-MSC-ExoGelMA MNsSustained release up to 72 hPreclinicalImproved retention, functional recovery and reduced neuroinflammationImplantation route and long-term safety need validation[19,94,144–147]Cardiac fibrosis after MIHUCMSC-ExoBiodegradable MN patchElectroporation-loaded miR-29bPreclinicalImproved infarct-zone retention and antifibrotic effectsClinical delivery route remains challenging[82,96,148–150]Rheumatoid arthritisMilk-derived exosomesCryomicroneedlesTNF-alpha siRNA loading and acupoint administrationPreclinicalLocalized TNF-alpha silencing and anti-inflammatory effectsStandardized dose and immunogenicity unclear[102]PsoriasisTreg-derived exosomes and DMFrExo@DMF MNsLocal immunomodulatory drug-exosome complexPreclinicalReduced inflammation and promoted Treg differentiationLong-term immune effects require validation[50]Intervertebral disc degenerationBMSC-ExoThreaded MNsmiR-378-loaded engineered exosomesPreclinicalImproved anchorage, sustained release and AF repairSurgical access and mechanical integration remain issues[37,38,40,158] Disease Applications, MN-Exosome Design Features and Evidence Levels Translational Roadmap, Future Outlook and Limitations MN-exosome systems offer a compelling strategy for localized and precision therapy, but their clinical translation requires a rigorous development framework. First, exosome identity and potency must be defined with standardized characterization, impurity profiling and release assays in accordance with EV reporting principles.4–6 Second, MN materials and architectures must be optimized not only for insertion strength and release kinetics but also for preservation of vesicle integrity during fabrication, storage and use.98–100 Third, scalable manufacturing remains unresolved: batch-to-batch consistency, sterility assurance, cost-effective production, cryostability or lyophilization, packaging and cold-chain requirements must be addressed before commercialization.70 Fourth, preclinical studies should move beyond short-term small-animal efficacy and include biodistribution, cellular uptake, dose-response relationships, repeat-dose toxicity, immunogenicity, local tissue reactions, degradation products and long-term functional outcomes. Finally, regulatory translation will require clear definitions of the active substance, mechanism-based potency assays and clinically meaningful endpoints. A proposed workflow from exosome isolation and engineering to MN fabrication, therapeutic delivery and clinical translation is shown in Figure 8, and the major scientific, engineering, regulatory and commercialization challenges are summarized in Table 7. Proposed workflow and translational roadmap for MN-assisted exosome delivery. The schematic summarizes exosome source selection, isolation, characterization, engineering, MN fabrication, quality control, local delivery, biodistribution and uptake evaluation, therapeutic efficacy assessment, safety testing and clinical translation. Created by the authors with BioRender.com based on the literature summarized in this Review. Table 7Translational Roadmap for MN-Assisted Exosome DeliveryChallenge DomainKey IssuesRecommended ActionsRelevant Section/TableScientific evidenceExosome heterogeneity, unclear active cargo, limited mechanism validationDefine source, cargo, target cells and mechanism-based potency assaysMolecular Composition and Information Transfer Function–1.5; Tables 1-3Engineering designLoading efficiency, vesicle protection, release profile and tissue penetrationMatch MN platform, matrix and loading mode to disease anatomy and microenvironmentSynergistic Effects of Exosomes and Microneedle Delivery Systems–3; Table 4 and Table 5Preclinical evaluationLimited biodistribution, uptake, PK/PD and repeat-dose toxicity dataAdd biodistribution, cellular uptake, dose-response, local tissue reaction and long-term efficacy assaysPrecision Applications of Microneedle-Delivered Exosome Systems in Tumor and Disease Treatment; Table 6Manufacturing and QCBatch variability, sterility, endotoxin, storage and scale-upDevelop GMP-compatible isolation, sterile processing, release criteria and storage protocolsTranslational RoadFigure, Future Outlook and Limitations; Table 2 and Table 3Regulatory/commercializationUnclear product classification, potency release criteria and clinical endpointsDefine active substance, critical quality attributes, potency assay and feasible first-in-human indicationsTranslational RoadFigure, Future Outlook and Limitations; Figure 8 Translational Roadmap for MN-Assisted Exosome Delivery Acknowledgments The authors thank all researchers whose work was cited in this Review. No professional medical writing assistance was used. Funding Statement The National Natural Science Foundation of China (82301281); Shandong Provincial Natural Science Foundation (ZR2025MS1181); Key R&D Project of Shandong Province (2022CXPT023); Scholar project of Yantai’s “Double Hundreds Plan”(2024011). Abbreviations MNs, microneedles; EXOs, exosomes; MSC-Exo, mesenchymal stem cell-derived exosomes; ADSC-Exo, adipose-derived stem cell exosomes; BMSC, bone marrow-derived mesenchymal stem cells; CNP, cell nanoporation; ISF, interstitial fluid; GOx, glucose oxidase; ICB, immune checkpoint blockade; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; GPC-1, glypican-1; TNF-alpha, tumor necrosis factor-alpha; IL-10, interleukin-10; NF-kappaB, nuclear factor kappa B; alpha-SMA, alpha-smooth muscle actin; Col I, type I collagen; MOF, metal-organic framework; MRSA, methicillin-resistant Staphylococcus aureus; SCI, spinal cord injury; HUCMSC, human umbilical cord mesenchymal stem cells; RA, rheumatoid arthritis; IRI, ischemia-reperfusion injury; IUAs, intrauterine adhesions; VEGF-A, vascular endothelial growth factor A; PDGF-BB, platelet-derived growth factor BB; IVDD, intervertebral disc degeneration; AF, annulus fibrosus; ECM, extracellular matrix; MVBs, multivesicular bodies; ROS, reactive oxygen species; HUVECs, human umbilical vein endothelial cells; HA, hyaluronic acid; GelMA, gelatin methacryloyl; NIR, near-infrared. Data Sharing Statement No new datasets were generated or analyzed in this Review. All data discussed are derived from previously published studies cited in the reference list. Ethics Approval and Informed Consent Not applicable. This article is a review of previously published literature and did not involve new studies with human participants, human data, human tissue, or animals performed by the authors. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References Associated Data Data Availability Statement No new datasets were generated or analyzed in this Review. All data discussed are derived from previously published studies cited in the reference list.